TY - A2的cif Mauro AU -莫特,约瑟夫•AU - Maheshwari重非盟-巴苏,Nayanika AU -狄龙,帕特里克AU -布雷迪,Kevin AU -熊,哈利AU -米勒德,崔西PY - 2022 DA - 2022/02/23 TI -一种罕见的大舰艇血管炎后检查点抑制剂治疗和Pegfilgrastim SP - 7295305六世- 2022 AB -抑制剂(cpi)和Pegfilgrastim检查站,长效生长因子代理,目前癌症治疗是至关重要的组成部分。几种不良事件(ira)结肠炎和肺炎等的毒性与CPI治疗有关。然而,大舰艇血管炎继发于CPI利用率只有罕见的病例报告和案例系列报道。有趣的是,大舰艇血管炎也被报告为一种罕见的并发症pegfilgrastim使用。我们提出一个59岁的女性离开舞台活动花絮(过度)三阴性乳腺癌新辅助化疗前接受新辅助decitabine和pembrolizumab (NAC)。南汽包括标准治疗剂量密集的阿霉素和环磷酰胺(ddAC)支持pegfilgrastim使用每周卡铂和紫杉醇紧随其后。在收到她的第二个周期的ddAC pegfilgrastim,病人报告五天的左肩和手臂疼痛。随后的CT影像表现壁增厚和左锁骨下动脉周围的炎性改变,主动脉弓,左颈动脉,颈内动脉近端无名动脉,中期及其分支血管。这些发现非常大的卡车血管炎有关。不包括CPI疗法和pegfilgrastim使用,没有额外的煽动事件或药物,病人暴露于指出与大船血管炎有关。 We present this case to report on this rare but severe complication from commonly utilized agents in cancer treatment. We also extend the possibility of large-vessel vasculitis development in relation to the COVID-19 vaccine due to shared ingredients found in both the vaccine and pegfilgrastim. It is important to outline the treatment used for such a complication as no standardized treatment has been established for large-vessel vasculitis caused by CPI therapy or pegfilgrastim use. SN - 2090-6706 UR - https://doi.org/10.1155/2022/7295305 DO - 10.1155/2022/7295305 JF - Case Reports in Oncological Medicine PB - Hindawi KW - ER -